Biohaven Ltd (BHVN)
40.69
+0.79
(+1.98%)
USD |
NYSE |
May 03, 16:00
40.68
-0.01
(-0.02%)
Pre-Market: 20:00
Biohaven Cash from Financing (Quarterly): 245.24M for Dec. 31, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 245.24M |
| September 30, 2023 | -39.66M |
| June 30, 2023 | -20.34M |
| March 31, 2023 | 26.67M |
| Date | Value |
|---|---|
| December 31, 2022 | 530.18M |
| September 30, 2022 | 127.54M |
| June 30, 2022 | 86.84M |
| March 31, 2022 | 23.03M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-39.66M
Minimum
Sep 2023
530.18M
Maximum
Dec 2022
122.44M
Average
56.75M
Median
Cash from Financing (Quarterly) Benchmarks
| Amgen Inc | -1.708B |
| Eli Lilly and Co | -311.30M |
| Regeneron Pharmaceuticals Inc | 47.10M |
| Viking Therapeutics Inc | 606.04M |
| Alnylam Pharmaceuticals Inc | 28.91M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -114.88M |
| Cash from Investing (Quarterly) | -3.914M |
| Free Cash Flow | -334.77M |
| Free Cash Flow Per Share (Quarterly) | -1.441 |
| Free Cash Flow Yield | -11.56% |